Bristol Myers Squibb today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary ...
SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated ...
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting. Updated data from studies like EV-302 and ...
Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback